StockNews.AI
CLNN
StockNews.AI
2 days

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

1. Clene Inc. announced participation in Maxim Growth Summit on neurodegenerative diseases. 2. Management will host 1x1 investor meetings to attract further investment. 3. Clene focuses on therapies for ALS, MS, and other neurological conditions. 4. CNM-Au8® targets mitochondrial health and reduces oxidative stress. 5. Company's presence at Summit indicates confidence in its innovative therapies.

3m saved
Insight
Article

FAQ

Why Bullish?

Participation in a summit can lead to increased investor interest and potential funding. Historical examples include stocks that rallied post-conference attendance.

How important is it?

The article discusses Clene's strategic initiatives in a high-demand therapeutics area, enhancing visibility and investment appeal.

Why Short Term?

The summit is imminent (October 22), which could drive immediate investor interest.

Related Companies

MSFTINCY
October 15, 2025 08:30 ET  | Source: Clene Inc. SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a panel discussion at the Maxim Growth Summit and host 1x1 investor meetings. Date: October 22, 2025Location: New York City, NYPanel Discussion: Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories 1x1 Meetings: Please contact your Maxim representative About CleneClene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn. Investor ContactKevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com617-283-2856

Related News